Oriola to record an impairment of approximately EUR 16 million related to its joint venture Kronans Apotek

Oriola Corporation Stock Exchange Release 19 December 2024 at 2 p.m. EET

Oriola to record an impairment of approximately EUR 16 million related to its joint venture Kronans Apotek

The integration in Oriola’s joint venture company Kronans Apotek has been more time-consuming than originally anticipated and the transition to one common ERP system has required more efforts than expected. Due to this, Kronans Apotek will record a goodwill impairment of approximately 373 million Swedish krona in its fourth quarter results.

Oriola’s share of the impairment is approximately 187 million Swedish krona or approximately 16 million euros, and will be recorded in the share of results in joint venture in the fourth quarter.

The value of Oriola’s investment in Kronans Apotek after the impairment totals approximately 214 million euros.

The impairment will be recorded in Oriola’s fourth quarter 2024 results and will have no effect on the Group’s cash flow or adjusted EBIT. Oriola’s outlook for 2024 remains unchanged. Oriola will publish its Financial Statements Release for 2024 on 4 March 2025.

Further information:

Mats Danielsson
CFO
tel. +358 50 394 8575
email: mats.danielsson@oriola.com

Mikael Wegmüller
VP, Communications and Sustainability
tel. +356 40 7762 314
email: mikael.wegmuller@oriola.com

Distribution:
Nasdaq Helsinki Ltd.
Key media